{
  "meta": {
    "timestamp": "2025-01-06T14:17:50.057145",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Spyre Therapeutics Inc.",
      "symbol": "SYRE",
      "analysis": {
        "historical": {
          "risk_score": 70,
          "key_risks": [
            "Clinical trial risks due to early-stage pipeline with no commercially available products",
            "Regulatory hurdles and potential delays or rejections from agencies like the FDA",
            "Dependence on external funding, with long-term financial stability uncertain",
            "Highly competitive IBD treatment market with numerous established players",
            "Legal investigation by Pomerantz LLP raising concerns about potential misconduct"
          ],
          "controversies": [
            "Ongoing legal investigation by Pomerantz LLP on behalf of investors",
            "Potential reputational damage and financial liabilities from legal issues"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Focus on addressing unmet medical needs in inflammatory bowel disease (IBD)"
          ],
          "governance_issues": [
            "Potential governance concerns due to legal investigation and reliance on external funding"
          ],
          "recommendation": "caution",
          "confidence_score": 80
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Spyre Therapeutics Reports Third Quarter 2024 Financial Results and ...",
              "snippet": "WALTHAM, Mass., Nov. 7, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (\"Spyre\" or the \"Company ... The Company expects to initiate a Phase 2 clinical trial in 2025 that is intended to include each of our rational combinations, as well as all three of our lead monotherapy programs. ... The failure of Spyre to exercise or enforce any right or ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:19.098138+00:00",
              "published_date": null,
              "source_hash": "0145b694e058e866dc41e520f85d6b32"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics",
              "snippet": "Engineering for new heights in the treatment of Inflammatory Bowel Disease. Spyre Therapeutics is developing potential best-in-class antibodies, rational therapeutic combinations, and precision immunology approaches with the goal of creating Inflammatory Bowel Disease (IBD) therapies with uncompromising efficacy and convenience.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.136927+00:00",
              "published_date": null,
              "source_hash": "5b0a54cd604d99cbcb2eed37547672a1"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Announces Positive Interim Results from Phase 1 ...",
              "snippet": "WALTHAM, Mass., Nov. 12, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \"Company\" or \"Spyre\"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:19.098218+00:00",
              "published_date": null,
              "source_hash": "441c04de2c8fbd2220d92c8633c429a7"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Announces Grants of Inducement Awards",
              "snippet": "Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \"Company\" or \"Spyre\"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:19.098229+00:00",
              "published_date": null,
              "source_hash": "6eb1d67b571c8458b2e4d2c3d9b237e5"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials ...",
              "snippet": "WALTHAM, Mass., Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \"Company\" or \"Spyre\"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.137000+00:00",
              "published_date": null,
              "source_hash": "e93e1e24488661cc45c4d6eaab2c7ede"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Announces Grants of Inducement Awards",
              "snippet": "WALTHAM - Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the 'Company' or 'Spyre'), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease ('IBD'), today announced that Spyre's independent Compensation Committee ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:19.098249+00:00",
              "published_date": null,
              "source_hash": "1b867a38ba29a72c841570fe72cc9cf6"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial ...",
              "snippet": "Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \"Company\" or \"Spyre\"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.137014+00:00",
              "published_date": null,
              "source_hash": "387f2278f8340fd36c148a903e061fac"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics to Host Conference Call and Webcast to Report ...",
              "snippet": "Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \"Company\" or \"Spyre\"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:19.098269+00:00",
              "published_date": null,
              "source_hash": "195a25008bdefe16c9c395b518b36c9d"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Inc. SYRE Overview - U.S. News",
              "snippet": "Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.137034+00:00",
              "published_date": null,
              "source_hash": "3725410dafce8c32f6f0e39c9323d366"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...",
              "snippet": "WALTHAM, Mass., Oct. 30, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of Inflammatory Bowel Disease (\"IBD\"), today ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:19.098288+00:00",
              "published_date": null,
              "source_hash": "232bd8f8dfb8a48290cbfc233a26fbf4"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies",
              "snippet": "Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE ... has initiated dosing of healthy volunteers in Phase 1 clinical trials of two investigational half-life extended anti ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:21.861051+00:00",
              "published_date": "2024-12-02T00:00:00+00:00",
              "source_hash": "e6ca98abae5e4d41ccb84c80e7936086"
            },
            {
              "url": "",
              "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE",
              "snippet": "NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. (\"Spyre\" or the \"Company\") (NASDAQ:SYRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:27.718540+00:00",
              "published_date": "2025-01-03T17:08:00+00:00",
              "source_hash": "c741046b0fd857e94942ca7bebae96eb"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Announces Grants of Inducement Awards",
              "snippet": "WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \"Company\" or \"Spyre\"), a clinical-stage biotechnology company utilizing best ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:33.867114+00:00",
              "published_date": "2025-01-03T14:20:00+00:00",
              "source_hash": "b2c292b59c7a1f16022b132a2e4b096d"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodies",
              "snippet": "Earlier this year, Spyre Therapeutics dosed the first subjects in a Phase I clinical trial of SPY001 for treating IBD. \"Spyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:21.861162+00:00",
              "published_date": "2024-12-03T21:53:00+00:00",
              "source_hash": "729dc7c0cb02d75a1e5502669146c5ca"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics announces first participants dosed in Phase 1 trial",
              "snippet": "Spyre Therapeutics (SYRE) announced that it has initiated dosing of healthy volunteers in Phase 1 clinical trials of two investigational half-life extended anti-TL1A monoclonal antibodies.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. clinical trial failures",
              "retrieved_at": "2025-01-06T21:17:21.861172+00:00",
              "published_date": "2024-12-02T13:05:00+00:00",
              "source_hash": "ad4e1cc10dab4e15d90e5769dbe37160"
            },
            {
              "url": "",
              "title": "Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics",
              "snippet": "Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) portfolio Spyre, the second spinout from Paragon Therapeutics, is advancing a pipeline of product candidates, led by SPY001 and SPY002, that are potentially best-in-class antibodies targeting a 4 b 7 and TL1A, respectively, and which are ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:24.989436+00:00",
              "published_date": null,
              "source_hash": "bc7b123a547c0af7cea4c8d80b8f82c7"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Announces Positive Interim Results from Phase 1 ...",
              "snippet": "Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-\u03b14\u03b27 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing ... Pending regulatory feedback, Spyre plans to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:24.989537+00:00",
              "published_date": null,
              "source_hash": "a3a9a9b3a803fc758af203b4f8586b73"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics, Inc. | Investor Relations - Press Releases",
              "snippet": "WALTHAM, Mass., Nov. 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the \"Company\" or \"Spyre\"), a development-stage biotechnology company, today announced its name change to Spyre Therapeutics, Inc. Effective as of market open on November 28, 2023, Spyre will trade on Nasdaq under the ticker symbol \"SYRE\".The name change follows the acquisition of privately held Spyre ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:24.989565+00:00",
              "published_date": null,
              "source_hash": "fe35cd8ef1e609dcd7b1a2e188d65234"
            },
            {
              "url": "",
              "title": "Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics ...",
              "snippet": "WALTHAM, Mass., Nov. 27, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) (the \"Company\" or \"Spyre\"), a development-stage biotechnology company, today announced its name change to ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:24.989576+00:00",
              "published_date": null,
              "source_hash": "2903ccb4b880b4653431b4457089a87b"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Reports Third Quarter 2024 Financial ... - BioSpace",
              "snippet": "WALTHAM, Mass., Nov. 7, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (\"Spyre\" or the \"Company\") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:24.989586+00:00",
              "published_date": null,
              "source_hash": "39e24ac75c99829272b322e08d6825ee"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials ...",
              "snippet": "WALTHAM, Mass., Dec. 2, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \"Company\" or \"Spyre\"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:24.989596+00:00",
              "published_date": null,
              "source_hash": "e054d5583b8e71f38494ea214ab81e22"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials ...",
              "snippet": "Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the \"Company\" or \"Spyre\"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:24.989605+00:00",
              "published_date": null,
              "source_hash": "ffd41b94a1c1c293824182cb1dd28f65"
            },
            {
              "url": "",
              "title": "About | Spyre Therapeutics",
              "snippet": "VP, Regulatory Affairs Our portfolio of potentially best-in-class antibodies was discovered and developed by our partner, Paragon Therapeutics. ... Paragon Therapeutics. Spyre is the second company that was founded upon technology spun out of Paragon, a group of leading entrepreneurial scientists and investors with extensive monoclonal antibody ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:24.989614+00:00",
              "published_date": null,
              "source_hash": "c2bc5aa4218f8811c408cebf2259462f"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics, Inc. | Investor Relations - Company Overview",
              "snippet": "Spyre Therapeutics is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. Spyre's pipeline includes extended half-life antibodies targeting a4\u00df7 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:24.989626+00:00",
              "published_date": null,
              "source_hash": "110015b40d565578a39c8e54595e3b37"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics: Different Name, Same Tune",
              "snippet": "Spyre Therapeutics is headquartered just outside of Boston in Waltham, MA. The company's lead asset at this time is a monoclonal antibody and a4b7 inhibitor currently dubbed SPY001 which is in ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:33.867146+00:00",
              "published_date": "2024-12-13T02:42:00+00:00",
              "source_hash": "c0cf0051d3ad9ce276b72e167d3e4cee"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by MetLife Investment Management LLC",
              "snippet": "MetLife Investment Management LLC boosted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 129.1% during the third quarter, according to its most recent 13F filing with the SEC.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:27.718639+00:00",
              "published_date": "2024-12-08T00:00:00+00:00",
              "source_hash": "933141163129d4ef64f69db053c9dbbe"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics is Now Oversold (SYRE)",
              "snippet": "In trading on Monday, shares of Spyre Therapeutics Inc (Symbol: SYRE) entered into oversold territory, hitting an RSI reading of 29.6, after changing hands as low as $22.79 per share. By ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. regulatory rejections",
              "retrieved_at": "2025-01-06T21:17:27.718648+00:00",
              "published_date": "2024-12-23T17:21:00+00:00",
              "source_hash": "73fa4572e5098b02d0878dd4c3281e93"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics' SPY001 shows efficacy, safety in Phase 1 ... - Nasdaq",
              "snippet": "Spyre Therapeutics (SYRE) announced positive interim Phase 1 data from its first-in-human trial of SPY001, an investigational novel, extended half-life monoclonal antibody targeting alpha4beta7.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.137024+00:00",
              "published_date": null,
              "source_hash": "3fb8dc596ae16d04d8a05025636db880"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics, Inc. (SYRE) Company Profile & Overview - Stock Analysis",
              "snippet": "Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the \u03b14\u03b27 integrin being developed for the treatment of IBD (ulcerative colitis and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.137043+00:00",
              "published_date": null,
              "source_hash": "a9a858da8d6e5c3c51f6f5bd802f71a9"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics, Inc. (SYRE) - Yahoo Finance",
              "snippet": "The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.137058+00:00",
              "published_date": null,
              "source_hash": "769208ab1c37343f72bc3af150351f2c"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics, Inc. Common Stock (SYRE) - Nasdaq",
              "snippet": "Discover real-time Spyre Therapeutics, Inc. Common Stock (SYRE) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.137067+00:00",
              "published_date": null,
              "source_hash": "d5c74e5241e924c6694e757cc7434537"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics, Inc. | Investor Relations - Press Releases",
              "snippet": "Spyre Therapeutics is a biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.137076+00:00",
              "published_date": null,
              "source_hash": "8880398974a469a87b324f1a38c6d96e"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Reports Third Quarter 2024 Financial Results and ...",
              "snippet": "WALTHAM, Mass., Nov. 7, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. (\"Spyre\" or the \"Company\") (NASDAQ:SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:31.137085+00:00",
              "published_date": null,
              "source_hash": "2c7c87a233d0b4b5a055163a8c08f405"
            },
            {
              "url": "",
              "title": "SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYRE",
              "snippet": "NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. (\"Spyre ... The investigation concerns whether Spyre and certain ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:33.867019+00:00",
              "published_date": "2025-01-02T07:55:00+00:00",
              "source_hash": "6c1a3a79b670d87e558f60ea10c06c14"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Inc.",
              "snippet": "The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:33.867101+00:00",
              "published_date": "2025-01-03T00:00:00+00:00",
              "source_hash": "e3ffa02c83e4585396094f30e22a7c69"
            },
            {
              "url": "",
              "title": "Spyre Therapeutics Prices Public Offering Of About 7.28 Mln Shares At $27.50/shr",
              "snippet": "(RTTNews) - Spyre Therapeutics Inc. (SYRE) announced the pricing of its underwritten public offering of about 7.28 million shares of its common stock at a price to the public of $27.50 per share.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Spyre Therapeutics Inc. Spyre Therapeutics Inc. patient safety concerns",
              "retrieved_at": "2025-01-06T21:17:33.867124+00:00",
              "published_date": "2024-11-18T00:00:00+00:00",
              "source_hash": "a22906e92a37e98f793052e939919bf7"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Spyre Therapeutics Inc. clinical trial failures",
              "rationale": "Investigate potential risks related to the success of clinical trials, which could impact the company's financial stability and legal standing.",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Spyre Therapeutics Inc. regulatory rejections",
              "rationale": "Examine any instances of regulatory hurdles or rejections by agencies like the FDA, which could delay or prevent product approvals.",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Spyre Therapeutics Inc. patient safety concerns",
              "rationale": "Look for any reports or controversies regarding patient safety in clinical trials, which could affect the company's reputation and ethical standing.",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:17:50.057153",
        "data_confidence": 80,
        "pattern_confidence": null
      }
    }
  ]
}